Aptar Pharma
Programme Partner
Aptar Pharma is an expert in nasal drug delivery, offering advanced intranasal systems and drug delivery services from design and manufacture, formulation development and clinical product manufacturing to post launch support. Our global network of GMP manufacturing sites help us accelerate and derisk drug product development, and our investments in R&D and innovation allow us to offer proven nasal drug delivery solutions to help improve patient outcomes across the globe. Aptar Pharma is part of AptarGroup, Inc.
Realeve
Innovation Partner
Realeve is a medical device company dedicated to developing innovative solutions for autonomic disorders with an initial focus on cluster headaches treartment, but with the ultimate goal of pioneering work in Blood Brain Barrier permeability. This MRI-compatible neurostimulator device (FDA breakthrough) offers ondemand stimulation of the sphenopalatine ganglion (SPG), a key nerve structure involved in autonomic disorders by regulating blood brain barrier flow/permeability. The Pulsante System has been successfully implanted in over 700 patients in the US/Europe, with promising results, including a randomized controlled trial published in The Lancet.
Affilogic
Innovation Partner
Affilogic is leveraging the versatility of its proprietary Nanofitin® technology to design and develop targeted therapies in a variety of indications including CNS diseases. Nanofitins are small affinity proteins selective of chosen epitopes from targets of interest, acting as APIs or vectors. In particular, Affilogic has discovered Nanofitins against a series of BBB targets to promote receptor-mediated transcytosis. Several formats have been designed to transport APIs – proprietary or through co-development partnerships - such as full-length mAbs, enzymes and nucleic acids, into the brain.
SHIFTBIO
Platform Partner
SHIFTBIO is pioneering next-generation therapeutics for CNS diseases with our proprietary dtBBB-Natural Nanoparticle (NNP) platform. This AI-driven, dual-mechanism shuttle is engineered to effectively penetrate the Blood-Brain Barrier, achieving efficient delivery of diverse payloads like ASO, siRNA, and enzymes directly into the brain parenchyma. Backed by our predictable NNP Design AI™ and cGMP-ready manufacturing, we accelerate the development of breakthrough therapies, shifting the paradigm of CNS drug delivery.
Cambridge Design Partnership
Event Partner
Cambridge Design Partnership is an end-to-end innovation partner, propelling global brands and ambitious start-ups to success.
We build breakthrough products and services – from insight to ideas, prototypes to production – bringing innovation to life. Our teams are multi-disciplinary, uniting scientific rigor, design ingenuity, and engineering excellence for consumer, healthcare, and industrial clients.
People-centered, deeply collaborative, and – above all – expert, we’re uniquely positioned to shape the future for consumers, patients, and industry. Even our ownership model is innovative: We’re 100% owned by our employees, ensuring an open culture and a total commitment to your project’s success.
One partner. No barriers. Extraordinary results.
Synvivo
Event Partner
SynVivo develops advanced organ-on-chip platforms that model human vascular and barrier biology under physiologic flow. Its flagship SynBBB™ enables predictive assessment of CNS drug transport, antibody and viral vector delivery, and neuroinflammation using integrated TEER-on-chip sensing. Complementary models such as SynRAM™, SynTumor™, and VascuLink™ extend to immune, oncology, and multi-organ studies—offering scalable, human-relevant alternatives to animal testing.
CraniUS Therapeutics
Event Partner
CraniUS Therapeutics is pioneering the next frontier of neuro-implantable medicine. Its flagship platform—a fully implantable, refillable device—bypasses the blood-brain barrier to deliver therapeutic agents directly to targeted brain regions, dramatically reducing systemic side effects. Based in Baltimore and founded in 2021, CraniUS has been recognized by the Maryland Tech Council as the 2025 Emerging Life Sciences Company of the Year for its breakthrough approach to treating brain tumors, neurodegeneration, and other complex neurological conditions.
Biomere
Exhibition Partner
Biomere is a growing preclinical contract research organization (CRO) based in the greater Boston area (Worcester MA). Biomere’s facility includes multiple floors of vivarium space for rodents and large animals, and laboratory spaces. Our core areas of expertise are preclinical non-GLP PK/PD studies and early toxicology studies in rodent and large animal models. Our team of scientists have specialty expertise in CNS models that include surgical services and specialized dosing routes. Biomere is AAALAC accredited, OLAW Assured, DEA Licensed, and USDA Registered.
Pharma Journalist
Media Partner
Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.
Pharma Phorum
Media Partner
Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and connect pharmaceutical industry leaders and to equip them to thrive in healthcare’s evolving digital future.
BioPharma Asia
Media Partner
BioPharma Asia aims to keep its readers abreast of all developments in Manufacturing, Development, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters associated with only end-user companies. So, ensuring the information will always be guaranteed to remain timely, informative, and unbiased.
